Recombinant Human ARHGEF2 293 Cell Lysate

• Cat.No.: ARHGEF2-8732HCL

Specification

• Description: Antigen standard for Rho/Rac guanine nucleotide exchange factor (GEF) 2 (ARHGEF2), transcript variant 3 is a lysate prepared from HEK293T cells transiently transfected with a TrueORF gene-carrying pCMV plasmid and then lysed in RIPA Buffer. Protein concentration was determined using a colorimetric assay. The antigen control carries a C-terminal Myc/DDK tag for detection.
• Source: HEK 293 cells
• Species: Human
• Components: This product includes 3 vials: 1 vial of gene-specific cell lysate, 1 vial of control vector cell lysate, and 1 vial of loading buffer. Each lysate vial contains 0.1 mg lysate in 0.1 ml (1 mg/ml) of RIPA Buffer (50 mM Tris-HCl pH7.5, 250 mM NaCl, 5 mM EDTA, 50 mM NaF, 1% NP40). The loading buffer vial contains 0.5 ml 2X SDS Loading Buffer (125 mM Tris-Cl, pH6.8, 10% glycerol, 4% SDS, 0.002% Bromophenol blue, 5% beta-mercaptoethanol).
• Size: 0.1 mg
• Storage Instruction: Store at -80°C. Minimize freeze-thaw cycles. After addition of 2X SDS Loading Buffer, the lysates can be stored at -20°C. Product is guaranteed 6 months from the date of shipment.
• Applications: ELISA, WB, IP. WB: Mix equal volume of lysates with 2X SDS Loading Buffer. Boil the mixture for 10 min before loading (for membrane protein lysates, incubate the mixture at room temperature for 30 min). Load 5 ug lysate per lane.

Gene Information

• Gene Name: ARHGEF2 Rho/Rac guanine nucleotide exchange factor (GEF) 2 [ Homo sapiens ]
• Official Symbol: ARHGEF2
• Synonyms: ARHGEF2; Rho/Rac guanine nucleotide exchange factor (GEF) 2; rho/rac guanine nucleotide exchange factor (GEF) 2; rho guanine nucleotide exchange factor 2; GEF H1; KIAA0651; LFP40; P40; microtubule-regulated Rho-GEF; guanine nucleotide exchange factor H1; proliferating cell nucleolar antigen p40; Rho/Rac guanine nucleotide exchange factor 2; GEF; GEFH1; GEF-H1; FLJ45440; DKFZp547L106; DKFZp547P1516
• Gene ID: 9181
• mRNA Refseq: NM_001162383
• Protein Refseq: NP_001155855
• MIM: 607560
• UniProt ID: Q92974
• Chromosome Location: 1q21-q22
• Pathway: Cell death signalling via NRAGE, NRIF and NADE, organism-specific biosystem; G alpha (12/13) signalling events, organism-specific biosystem; GPCR downstream signaling, organism-specific biosystem; NRAGE signals death through JNK, organism-specific biosystem; Pathogenic Escherichia coli infection, organism-specific biosystem; Pathogenic Escherichia coli infection, conserved biosystem; Reelin signaling pathway, organism-specific biosystem
• Function: Rac GTPase binding; Rac guanyl-nucleotide exchange factor activity; Rho GTPase binding; Rho guanyl-nucleotide exchange factor activity; Rho guanyl-nucleotide exchange factor activity; guanyl-nucleotide exchange factor activity; metal ion binding; microtubule binding; protein binding; zinc ion binding

Reviews

10/09/2021

the manufacturer's commitment to delivering the ARHGEF2 protein in a timely manner is greatly appreciated.

05/02/2021

the ARHGEF2 protein demonstrates significant relevance and potential in various trial applications, primarily focusing on inflammation, angiogenesis, and tissue remodeling.

01/04/2021

Their prompt and knowledgeable assistance has the potential to solve any difficulties I may encounter during my experiments.

09/02/2020

The manufacturer maintains stringent quality control measures to ensure the purity and stability of the protein, minimizing experimental variability and maximizing the accuracy of the data obtained.

10/25/2019

The cost-effectiveness of the ARHGEF2 protein, competitive pricing, and the availability of bulk purchase options provided by the manufacturer also align with my budget considerations, allowing me to optimize my resources.

01/15/2019

Another advantage of the ARHGEF2 protein is its reliability and consistency, ensuring robust and reproducible results.

11/29/2018

the manufacturer's support plays a crucial role in the successful implementation of trials involving the ARHGEF2 protein.

10/26/2016

I am confident that my experimental needs will be met through their assistance, ensuring successful outcomes in my trials.

Q&As

What are the potential therapeutic implications of targeting ARHGEF2?

Targeting ARHGEF2 or its downstream effectors could hold therapeutic potential for various diseases. Given its role in cancer metastasis, inhibiting ARHGEF2 could help prevent or reduce tumor cell invasion and migration. Modulating ARHGEF2 activity could also be beneficial in cardiovascular diseases by regulating blood vessel contraction and cardiac hypertrophy. Furthermore, targeting ARHGEF2 in neurological disorders might help regulate neuronal development and synaptic plasticity.

Are there any known interacting partners of ARHGEF2?

ARHGEF2 can interact with multiple proteins to exert its functions. It has been reported to interact with and activate several Rho GTPases, including RhoA, RhoB, and RhoC. ARHGEF2 can also interact with other signaling molecules, such as focal adhesion kinase (FAK), paxillin, and Galpha12/13 proteins, to regulate cytoskeletal dynamics and cell adhesion.

Can ARHGEF2 interact with other proteins involved in cell signaling pathways?

Yes, ARHGEF2 can interact with several other proteins involved in cell signaling pathways. It can interact with integrin-associated proteins like vinculin and talin, as well as adherens junction proteins such as E-cadherin, β-catenin, and α-catenin. These interactions modulate cell adhesion and cytoskeletal dynamics. Additionally, ARHGEF2 can interact with signaling molecules like G-protein-coupled receptors (GPCRs), growth factor receptors, and non-receptor tyrosine kinases, enabling crosstalk between different signaling pathways.

What are the potential downstream effectors or signaling pathways regulated by ARHGEF2?

ARHGEF2 has been shown to activate RhoA, which in turn regulates a variety of downstream effectors and signaling pathways. This includes the Rho-associated protein kinase (ROCK) pathway, which controls actin-myosin contractility and cell shape changes, as well as the mDia and IRSp53 pathways involved in actin filament assembly. Additionally, ARHGEF2 can activate Rac1, which can activate JNK and p38 MAP kinase pathways to influence cell migration and invasion.

Are there any known genetic mutations or polymorphisms in the ARHGEF2 gene?

Yes, mutations in the ARHGEF2 gene have been associated with different disorders. In particular, loss-of-function mutations in ARHGEF2 have been linked to intellectual disability and developmental delay. These mutations can lead to altered Rho GTPase signaling, affecting cellular processes involved in neural development and cognition. Additionally, variations in the ARHGEF2 gene have been found to be associated with hypertension susceptibility in certain populations.

Are there any ongoing research efforts focused on ARHGEF2?

Yes, research on ARHGEF2 is ongoing. Scientists continue to investigate its role in various cellular processes and its involvement in different diseases. They are studying the mechanisms of ARHGEF2 activation, its interaction partners, and the downstream pathways it regulates. Additionally, efforts are being made to explore potential therapeutic strategies targeting ARHGEF2 for diseases such as cancer and neurological disorders.

What are the cellular processes and functions associated with ARHGEF2?

ARHGEF2 is involved in multiple cellular processes, including actin cytoskeleton organization, cell adhesion, cell migration, cell proliferation, and cell polarity. It regulates these processes by activating Rho GTPases, which in turn control the organization of the actin cytoskeleton and the dynamics of cell shape changes. ARHGEF2 is essential for various physiological processes, such as development, tissue homeostasis, and wound healing, and its dysregulation is associated with pathological conditions like cancer and cardiovascular diseases.

Is ARHGEF2 associated with any diseases or pathological conditions?

Yes, ARHGEF2 has been implicated in various diseases and pathological conditions. It has been found to be involved in cancer progression and metastasis by promoting cell migration, invasion, and epithelial-mesenchymal transition (EMT). ARHGEF2 has also been linked to cardiovascular diseases, such as hypertension and cardiac hypertrophy, as well as neuronal disorders, including epilepsy and intellectual disability.